Anthem Biosciences Ltd (ANTHEM) Announcements - Latest Exchange Filings with AI Summaries
Latest corporate announcements filed by Anthem Biosciences Ltd on NSE and BSE, with an AI summary of each filing.
Investors presentation for the financial results for the quarter and half year ended September 30, 2026.
Investor Presentation · 03 Nov 2026, 11:43 pm
Anthem Biosciences Reports Strong Q2FY27 Results With Record Margins Anthem Biosciences reported Q2FY27 consolidated revenue from operations of ₹5,940 Mn, up 7.9% YoY and 42.0% QoQ, driven by CRDMO sales of ₹5,093 Mn (up 9.2% YoY). EBITDA grew 24.1% YoY to ₹3,304 Mn with EBITDA margins expanding 610 bps YoY to 50.6%. PAT increased 21.9% YoY to ₹2,115 Mn with a 32.4% margin. For H1FY27, revenue reached ₹10,123 Mn, EBITDA stood at ₹5,059 Mn (46.2% margin), and PAT was ₹3,314 Mn. As of 30th Sep'26, net cash totaled ₹15,380 Mn.
Press release for the financial results for the quarter and half year ended September 30, 2026
Press Release · 03 Nov 2026, 11:37 pm
Anthem Biosciences Reports Strong Q2FY27 Results with PAT Up 21.9% YoY Anthem Biosciences reported a 7.9% YoY increase in Q2FY27 consolidated revenue from operations to ₹5,940 Mn (up 42.0% QoQ), led by CRDMO revenue of ₹5,093 Mn (up 9.2% YoY). EBITDA grew 24.1% YoY to ₹3,304 Mn with EBITDA margins reaching 50.6%, while PAT rose 21.9% YoY to ₹2,115 Mn with a 32.4% margin. For H1 FY27, revenue stood at ₹10,123 Mn, EBITDA at ₹5,059 Mn (46.2% margin), and PAT at ₹3,314 Mn. As of 30th Sep'26, the company held a net cash position of ₹15,380 Mn.
Submission of the outcome of the Board Meeting held on November 03, 2026, for approval of the Unaudited Financial results for the quarter and half year ended September 30, 2026.
Outcome · 03 Nov 2026, 11:30 pm
Submission of outcome of the Board Meeting approving the Unaudited Financial results for the quarter and half year ended September 30, 2026, on November 03, 2026
Financial Result · 03 Nov 2026, 11:24 pm
Anthem Biosciences Limited has submitted to the Exchange, the unaudited standalone and consolidated financial results for the period ended September 30, 2026.
Outcome · 03 Nov 2026, 11:23 pm
Anthem Biosciences Ltd - Financial Result for the Quarter ended 30th Sep'26 (Consolidated, INR Million) ■ Revenue: 5,940 (+7.9% YoY | +42.0% QoQ) ■ EBITDA: 2,715 (+24.3% YoY | +80.3% QoQ) ■ EBITDA Margin (%): 45.7 (+603 bps YoY | +970 bps QoQ) ■ PAT: 2,115 (+21.9% YoY | +76.3% QoQ) ■ EPS (INR): 3.72 (+21.6% YoY | +76.3% QoQ) Anthem Biosciences Ltd - Financial Result for the Quarter ended 30th Sep'26 (Consolidated, INR Million) Segmental Performance CRDMO ■ Revenue: 5,093 (+9.2% YoY | +49.4% QoQ) ■ EBIT: 3,663 (+28.1% YoY | +57.7% QoQ) ■ EBIT Margin (%): 71.9 (+1061 bps YoY | +377 bps QoQ) Speciality Ingredients ■ Revenue: 848 (+0.6% YoY | +9.5% QoQ) ■ EBIT: 431 (+4.4% YoY | +8.4% QoQ) ■ EBIT Margin (%): 50.8 (+185 bps YoY | -53 bps QoQ)
Earnings Call for the Unaudited Financial Results for the quarter and half year ended September 30, 2026
Intimation · 04 Nov 2026, 12:30 pm
Anthem Biosciences Schedules Q2 & H1 FY27 Earnings Call on 4th Nov'26 Anthem Biosciences Limited has scheduled an earnings conference call on 4th Nov'26 at 12:30 PM IST to discuss its unaudited standalone and consolidated financial results for the quarter and half-year ended 30th Sep'26 (Q2 & H1 FY27). Universal dial-in access numbers for participants include +91 22 6280 1488 and +91 22 7115 8869, alongside international toll-free options for the USA, UK, Hong Kong, and Singapore.
To consider and approve the financial results for the period ended September 30, 2026
Intimation · 03 Nov 2026, 5:30 am
Anthem Biosciences Limited has informed the Exchange about Board Meeting to be held on 03-Nov-2026 to inter-alia consider and approve the Unaudited Financial results of the Company for the Half Yearly ended September 2026 .
Intimation · 03 Nov 2026, 5:30 am
Anthem Biosciences Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 03/11/2026 ,inter alia, to consider and approve Unaudited Standalone and ....
Intimation · 03 Nov 2026, 5:30 am
Anthem Biosciences Schedules Board Meeting to Approve Q2 and H1'27 Results Anthem Biosciences Limited announced that its Board of Directors will meet on 3rd Nov'26 to consider and approve the unaudited standalone and consolidated financial results for the quarter and half year ended 30th Sep'26. In accordance with SEBI insider trading regulations, the trading window for dealing in the company's equity shares remains closed from 1st Oct'26 until the close of trading hours on 5th Nov'26, which is 48 hours after the declaration of the financial results.
Intimation of the settlement of Upside Sharing Arrangement
Others (Uncategorized) · 09 Sept 2026, 3:44 am
Anthem Biosciences Settles INR 1,276.83 Million Upside Sharing Arrangement Anthem Biosciences has executed the settlement of an upside sharing arrangement amounting to approximately INR 1,276.83 million. The payout, arising from the divestment by Viridity Tone LLP, has been settled with Upside Principal Shareholders—Mr. Ajay Bhardwaj, Mr. Ganesh Sambasivam, and Mr. K. Ravindra Chandrappa. The transaction was implemented pursuant to the Waiver-cum-Amendment Agreement dated 30th Dec'24 under Regulation 26(6) of SEBI LODR Regulations, following shareholder approval secured at the AGM held on 22nd Jul'26.
Transcript of Earnings Conference Call held on July 22, 2026.
Transcript · 27 Jul 2026, 4:22 pm
Anthem Biosciences Limited has submitted the Exchange the voting results and a copy of scrutinizer report of the 20th Annual General Meeting of the Company held on July 22, 2026
Annual General Meeting · 24 Jul 2026, 9:36 pm
Anthem Biosciences Limited has informed the Exchange regarding the Proceedings of the 20th Annual General Meeting held on Wednesday, July 22, 2026
Annual General Meeting · 23 Jul 2026, 5:23 am
Audio recording of Earnings Call for the quarter ended June 30, 2026.
Audio / Video · 22 Jul 2026, 11:37 pm
Anthem Biosciences Makes Q1 FY27 Earnings Call Recording Available Anthem Biosciences announced that the audio recording for its earnings call discussing the unaudited financial results for the quarter ended Jun 30, 2026, has been made available. The recording, which covers discussions with analysts and institutional investors, was published on the company's website on Jul 22, 2026. This action is in compliance with SEBI's Listing Obligations and Disclosure Requirement Regulations, 2015.
Revised Press Release on Unaudited Financial Results for the quarter ended June 30, 2026
Press Release · 22 Jul 2026, 12:55 am
Anthem Biosciences Reports Weak Q1FY27 Performance Driven by Revenue Decline Anthem Biosciences reported weak Q1FY27 results for the quarter ended 30th Jun'26, impacted by timing shifts in deliveries. Consolidated Revenue from Operations declined 22.6% YoY to ₹4,182 Mn. EBITDA fell 18.1% YoY to ₹1,755 Mn, though margins improved to 39.6%. Profit After Tax (PAT) decreased 11.7% YoY to ₹1,199 Mn, with PAT margins at 27.1%. The CRDMO segment, a key revenue driver, saw a significant 24.7% YoY drop. Management states underlying demand remains strong and expects a recovery in the year's second half.
Revised Investor Presentation for Unaudited Consolidated Financial Results of the Company for the quarter ended June 30, 2026
Investor Presentation · 22 Jul 2026, 12:51 am
Anthem Biosciences Q1FY27 Results Weighed by Delivery Timing Shifts Anthem Biosciences reported a weak Q1FY27, with revenues declining 22.6% YoY to ₹4,182 Mn due to timing shifts in key customer deliveries. The CRDMO segment fell 24.7% YoY. Despite the revenue drop, EBITDA margin improved 153 bps YoY to 39.6%, driven by cost efficiencies. EBITDA decreased 18.1% YoY to ₹1,755 Mn, and PAT fell 11.7% YoY to ₹1,199 Mn. Management noted strong underlying demand and expects to capture momentum from scheduled deliveries in the second half of the year. Net cash stood at ₹17,197 Mn.
Press Release on Consolidated Financial Results for the quarter ended June 30, 2026
Press Release · 21 Jul 2026, 10:24 pm
Anthem Biosciences Reports Weak Q1FY27 on Delivery Shifts; Margins Remain Robust Anthem Biosciences reported weak Q1FY27 results for the quarter ending 30 Jun'26, impacted by timing shifts in customer deliveries. Revenue from Operations declined 22.6% YoY and 31.5% QoQ to ₹4,182 Mn. The CRDMO segment saw a 24.7% YoY drop. Despite the top-line weakness, EBITDA margin was strong at 39.6%, although EBITDA fell 18.1% YoY to ₹1,755 Mn. Profit After Tax decreased 11.7% YoY to ₹1,199 Mn, with a PAT margin of 27.1%. Management notes strong underlying demand, with deliveries concentrated in H2.
Investor Presentation on Unaudited Consolidated Financial Results for the quarter ended June 30, 2026`
Investor Presentation · 21 Jul 2026, 10:22 pm
Anthem Biosciences Q1FY27 Revenue Declines YoY, but Margins Expand Anthem Biosciences reported a weak Q1FY27, with revenue from operations down 22.6% YoY to ₹4,182 Mn, driven by a 24.7% drop in its core CRDMO segment. Profit after tax fell 11.7% YoY to ₹1,199 Mn. However, operational efficiency led to margin expansion, with EBITDA margin improving 153 bps YoY to 39.6% and PAT margin rising to 27.1%. Management attributes the revenue decline to timing shifts in deliveries, expecting a stronger second half. The company maintained a robust net cash position of ₹17,197 Mn.
Financials Results for the quarter ended June 30, 2026
Financial Result · 21 Jul 2026, 10:17 pm
Anthem Biosciences Reports Q1FY27 Results with YoY Decline in Revenue and Profit Anthem Biosciences reported a consolidated net profit of ₹1,199.4 Mn for Q1FY27, down 11.7% YoY but up significantly QoQ from ₹1,897.6 Mn. Revenue from operations declined 22.6% YoY to ₹4,182.2 Mn. Sequentially, revenue fell 31.5%. Profit before tax stood at ₹1,445.8 Mn, a 22.4% YoY decrease. The CRDMO segment, contributing 81.5% of revenue, saw a 24.7% YoY decline to ₹3,408.0 Mn. The Speciality Ingredients segment also fell 11.5% YoY. Basic EPS for the quarter was ₹2.13.
Outcome of the Board Meeting held on Tuesday, July 21, 2026
Outcome · 21 Jul 2026, 10:06 pm
Anthem Biosciences Ltd - Financial Result for the Quarter ended 30th Jun'26 (Consolidated, INR Mn) ■ Revenue: 4,182 (-22.6% YoY | -31.5% QoQ) ■ EBITDA: 1,506 (-21.4% YoY | -43.7% QoQ) ■ EBITDA Margin (%): 36.0 (+55 bps YoY | -774 bps QoQ) ■ PAT: 1,199 (-11.7% YoY | -36.8% QoQ) ■ EPS (INR): 2.11 (-12.8% YoY | -36.8% QoQ) Anthem Biosciences Ltd - Financial Result for the Quarter ended 30th Jun'26 (Consolidated, INR Mn) Segmental Performance CRDMO ■ Revenue: 3,408 (-24.7% YoY | -33.5% QoQ) ■ EBITDA: 0.0 ■ EBITDA Margin (%): 0.0 Speciality Ingredients ■ Revenue: 774 (-11.5% YoY | -21.1% QoQ) ■ EBITDA: 0.0 ■ EBITDA Margin (%): 0.0
Intimation of Schedule of Earnings Conference Call to discuss on Unaudited Standalone and Consolidated Financial Results for quarter ended June 30, 2026
Intimation · 22 Jul 2026, 11:30 am
Anthem Biosciences Schedules Q1 FY27 Earnings Conference Call Anthem Biosciences (NSE: ANTHEM) will hold an earnings conference call on Wed, 22 Jul'26, at 11:30 AM IST. Management, including CEO Ajay Bhardwaj and CFO Gawir Baig, will discuss the unaudited standalone and consolidated financial results for the quarter ending 30 Jun'26. This event provides investors with an opportunity to receive an update on the company's performance and outlook directly from its leadership team. Further details on the call are available on the company's website.
Anthem Biosciences Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 21/07/2026 ,inter alia, to consider and approve Unaudited Standalone and ....
Intimation · 21 Jul 2026, 5:30 am
Anthem Biosciences Board Meeting Scheduled for Q1FY27 Results Anthem Biosciences' Board of Directors will meet on 21 Jul'26 to consider and approve the Unaudited Standalone and Consolidated Financial Results for the quarter ended 30 Jun'26. The trading window for dealing in the company's equity shares is closed from 01 Jul'26 until 23 Jul'26, which is 48 hours after the results declaration. This action complies with SEBI's insider trading regulations.
Letter to Shareholders providing the weblink and navigation path for accessing the Annual Report for the FY 2025-26 pursuant to Regulation 36(1)(b) of LODR.
Annual Report · 08 Jul 2026, 5:42 pm
Intimation of Revision in Credit Rating
Others (Uncategorized) · 03 Jul 2026, 6:05 pm
Anthem Biosciences' Long-Term Rating Upgraded by ICRA On Jul 03, '26, Anthem Biosciences announced a credit rating upgrade by ICRA for its bank facilities. The long-term rating was raised to '[ICRA]AA' from '[ICRA]AA-', with the outlook revised to 'Stable' from 'Positive'. This affects facilities totaling ₹275.5 Cr, including fund-based working capital of ₹175 Cr and a term loan of ₹67.5 Cr. The short-term rating of '[ICRA]A1+' was reaffirmed. This upgrade reflects an improved credit profile and applies to both existing and enhanced limits.
Newspaper advertisement regarding the completion of dispatch of notice of the 20th Annual General Meeting of the Company
Annual General Meeting · 02 Jul 2026, 12:01 am